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Introduction 
The list of drugs with the potential to trigger drug-
induced lupus erythematosus is mounting and 
understanding the timeline and presentation of 
these cases might help us better understand how 
to care for these patients. An antineoplastic drug, 
which is also a pyrimidine analogue, 5-fluorouracil 
(5-FU), has been linked to drug-induced subacute 
cutaneous lupus erythematosus (SCLE) when 
administered systemically. Murine studies have 
demonstrated a clear link between 5-FU, ultra-
violet B (UVB) radiation, and development of 
lupus-like lesions on the skin, suggesting that UVB 
light may play an integral role in the pathogenesis 
of this disease process [1]. A recent review found 
that overall, there was an increase of 12.6% in the 
reporting of drug-induced lupus secondary to the 
chemotherapeutic class of drugs between 2009 
and 2016, suggesting that the incidence of 
chemotherapy-induced lupus is on the rise [2]. We 
present a review of the literature relating to 
systemic 5-FU-induced lupus erythematosus to 
highlight the cutaneous side effects that can occur 
with pyrimidine analog antimetabolites. 
Table 1 summarizes all known reported cases of 
lupus erythematosus induced by either 5-FU or its 
prodrugs, capecitabine and uracil-tegafur. Cases 
with a prior history of systemic lupus 
erythematosus (SLE) or SCLE were excluded. Most 
cases of 5-FU-induced lupus occur in females with 
an average age of 67 years (median 67 years; 
range 49-78 years). This is consistent with a 
previous review of drug-induced SCLE, in which 
Abstract 
Drug-induced subacute cutaneous lupus 
erythematosus (SCLE) is the most common subtype 
of drug-induced systemic lupus erythematosus 
and has been associated with more than 100 
drugs. It presents weeks to months after initiation 
of the culprit medication. The eruption is typically 
in a photodistribution and it is marked by positive 
serology to anti-Ro (SSA) antibody. Systemic 5-
fluorouracil (5-FU) is a less-common culprit of 
drug-induced SCLE and its occurrence is likely 
dependent on exposure to ultraviolet light. Herein, 
we present a review of drug-induced lupus 
induced by the pyrimidine analog, 5-FU, and its 
prodrugs, capecitabine and uracil-tegafur. The 
search was carried out using the following terms: 
(PubMed: keywords included drug-induced lupus, 
5-fluorouracil, subacute cutaneous lupus 
erythematosus, capecitabine, uracil-tegafur, 
discoid lupus, systemic lupus erythematosus). 
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authors reported most cases occurred in females 
with a mean age of 59 years [2]. In the current 
series, SCLE represents the most common 
phenotype of drug-induced systemic lupus 
erythematosus, which can be seen in Figure 1. It 
manifests as erythematous annular plaques in 
sun-exposed areas and commonly is associated 
with a positive anti-Ro antibody (Figure 2). Most 
cases of SCLE occur within days to weeks after 
exposure to drug and resolve within 3 months. 
Topical corticosteroids, photoprotection, and 
discontinuation of the culprit drug are generally 
the mainstays of treatment. A few patients were 
also treated with hydroxychloroquine and/or 
systemic steroids. One case of 5-FU induced SCLE 
recurred when capecitabine was administered [3]. 
The most common underlying cancers reported 
were breast cancer and colorectal cancer. 
Chronic cutaneous lupus erythematosus is the 
second-most common subtype occurring with 
systemic administration of 5-FU and its analogues 
(Table 2). It tends to have a slower onset (months 
to years) and resolves over months. There is 
variable antinuclear antibody positivity in these 
cases. Systemic lupus erythematosus is the least 
common subtype to occur, with an onset of days 
to months and it tends to resolve within days to 
weeks. Antibody status was only reported for one 
of the cases, which had positive antinuclear 
antibody, anti-Smith, anti-Ro, and anti-La antibodies. 
 
Discussion 
Drug-induced lupus erythematosus was first 
reported by Hoffman, et al. in 1945 and was 
attributed to sulfadiazine treatment [4]. Drug-
induced lupus erythematosus can be classified 
into systemic drug-induced lupus erythematosus, 
drug-induced SCLE, and chronic cutaneous drug-
 
Figure 1. Lupus subtype induced by 5-fluorouracil/ 
capecitabine/ uracil-tegafur. A graphical representation of 
the frequency of lupus subtypes induced by 5-fluorouracil 
and its analogues. Most cases of drug-induced lupus 
erythematosus secondary to 5-fluorouracil and its 
analogues result in the subacute cutaneous lupus 
phenotype. 
   
Figure 2. Drug-induced subacute cutaneous lupus erythematosus. A) Erythematous annular plaques on the upper back, B) 
chest, and C) upper extremities. 
B A C 
Volume 25 Number 11| November 2019| 
25(11):1 
 
 
- 3 - 
Dermatology Online Journal  ||  Review 
induced lupus erythematosus, similar to 
idiopathic lupus erythematosus. Drug-induced 
SCLE and chronic cutaneous drug-induced lupus 
erythematosus are the forms which present with 
cutaneous involvement. The concept of drug-
induced SCLE was introduced in 1985 by Reed, et 
al. and was associated with hydrochlorothiazide 
[5]. Now, drug-induced SCLE is known to be the 
most common drug-induced lupus 
erythematosus subtype [6]. In fact, the occurrence 
of a drug as a cause of or as an exacerbating factor 
represents about 20% of newly diagnosed cases 
of SCLE [4]. Drugs associated with SCLE are 
typically photosensitizing agents and the most 
common culprits are hydrochlorothiazide, calcium 
channel blockers, and angiotensin-converting 
enzyme inhibitors [7]. Reports of drug-induced 
SCLE related to proton pump inhibitors and 
chemotherapy agents are increasing [2]. Less 
commonly, SCLE is associated with terbinafine, 
immunomodulators, and biologics [2].  
The pathogenesis of drug-induced lupus 
erythematosus is likely an interaction of genetic 
predisposition, drug biotransformation, and 
epigenetic dysregulation [7]. Regarding 5-FU-
induced SCLE, 5-FU is postulated to damage the 
basal layer of the epidermis, which may 
predispose these cells to the effects of UVB light 
[1]. Interestingly, mouse models of 5-FU-induced 
SCLE found that 5-FU alone without concomitant 
ultra-violet light (UVB) did not induce significant 
changes either clinically or histologically [8]. It has 
also been postulated that these 
chemotherapeutic agents translocate SSA/Ro to 
the surface of basal keratinocytes in a manner 
similar to UVB light [8, 9]. This observation 
suggests that the effects of UVB on keratinocytes 
damaged by 5-FU are integral in the pathogenesis 
of 5-FU-induced SCLE. 
 
Conclusion 
There are many drugs that can induce lupus 
erythematosus in a variety of patients. In our 
review we looked at patients who had different 
subtypes of lupus erythematosus and the majority 
exhibited cutaneous manifestations induced by 
systemic administration of drugs such as 5-FU, 
capecitabine, and uracil-tegafur. Our findings 
showed that the most common lupus subtype 
induced by these drugs is SCLE (56% of cases) and 
the least common was SLE (19% of cases). In most 
cases, the condition subsided with 
discontinuation of the culprit medication, 
photoprotection, and topical corticosteroids. 
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Table 1. Summary of drug-induced lupus erythematosus caused by 5-fluorouracil and its analogues. 
 
Dem 
Lupus 
Subtype 
Cancer 
Diagnosis Drug Morphology Distribution 
Antibodies 
U/ml 
Onset 
Rash TRR TRA TX Ref 
49 year-
old 
female  
SCLE 
Breast 
cancer  
capecitabine 
Annular red 
scaly patches 
Neck, chest, 
upper arms, 
forearms, 
hands 
 
Histone: Positive (2.3) 
Smith: Negative 
dsDNA: Negative 
Antinuclear antibody: 640 
Ro: Positive(>8) 
La:  (Not available) 
2 weeks 4-6 weeks 
Not 
available  
Topical steroid 
Photoprotection 
[8] 
50 year-
old 
female 
SCLE 
Colon 
cancer 
capecitabine 
Annular red 
itchy eruption 
Areas 
exposed to 
sunlight 
Histone: Not available 
Smith: Not available  
dsDNA: Not available  
Antinuclear antibody: Not 
available  
Ro: Positive 
La: Not available  
4 months 
Not 
available  
Not 
available  
Hydroxychloro-
quine 
Oral prednisone 
[9] 
54 year-
old 
female  
SLE 
Breast 
cancer  
capecitabine Not available  Face, chest 
Histone: Not available  
Smith: Not available  
dsDNA: Not available  
Antinuclear antibody: Not 
available  
Ro: Not available  
La: Not available  
4 days 11 days 
Not 
available  
Not available  [10] 
58 year-
old 
female  
DLE 
Rectal 
cancer  
 
capecitabine Not available  Face 
Histone: Negative 
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody: 160 
Ro: Negative 
La: Negative 
3 months 2 months 
Not 
available  
Not available  [11] 
64 year-
old 
female  
SCLE 
Colon 
Cancer  
5-fluorouracil  
Red scaly 
plaques  
Face, neck, 
forearms, 
hands 
Histone: Negative 
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody:160 
Ro: Positive (27.2) 
La: Not available  
2 weeks 2 weeks 
Not 
available  
Topical steroid 
Photoprotection 
[12] 
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64 year-
old 
female   
DLE 
Lung cancer  
 
uracil-tegafur  Not available  Face 
Histone: Not available  
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody: 80 
Ro: Negative 
La: Negative 
7 months 2 months 2 months Not available  [13] 
64 year-
old male   
SCLE 
Esophageal 
cancer 
5-fluorouracil  
Annular red 
plaques 
Photo-
exposed  
Histone: Negative 
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody: 320 
Ro: Negative 
La: Positive 
3 weeks 1 month 
Not 
available  
Topical steroid  
Photoprotection 
[14] 
50 year-
old 
female   
  
SCLE 
Colon 
cancer  
 
capecitabine 
Annular red 
itchy plaques 
Face, chest, 
arms 
Histone: Negative 
Smith: Not available  
dsDNA: Not available  
Antinuclear antibody: 1280 
Ro: Positive 
La: Not available  
3 weeks 2 weeks  
Not 
available  
Hydroxychloro-
quine 
Oral prednisone 
[15] 
67 year-
old 
female   
SCLE 
 
Colon 
cancer  
capecitabine 
Annular red 
patches  
Face, 
forearms, 
hands 
Histone: Not available  
Smith: Not available  
dsDNA: Not available  
Antinuclear antibody: 320 
Ro: Positive(200) 
La: Not available  
6 weeks 
Not 
available  
Not 
available  
Oral prednisone [16] 
68 year-
old 
female   
SLE 
Colon 
cancer 
capecitabine  Not available  
Not available  
 
 
Histone: Not available  
Smith: Not available  
dsDNA: Not available  
Antinuclear antibody: Not 
available  
Ro: Not available  
La: Not available  
Not 
available  
Not 
available  
Not 
available  
Hydroxychloro-
quine 
Methylpredni-
solone 
[17] 
70 year-
old 
female   
DLE 
Colon 
Cancer  
uracil-tegafur  
Annular 
Scaly pink/ 
violaceous/ 
red scaly 
plaques 
Face 
Histone: Not available  
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody: 40 
Ro: Positive(217.6) 
La: Positive (40.4) 
6 months 3 weeks 
Still 
elevated 
at 6 
months 
Not available  [7] 
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72 year-
old 
female   
SCLE 
Gastric 
cancer  
capecitabine 
Red, indurated 
papules and 
plaques  
Face, neck, 
chest, arms, 
hands 
Histone: Not available  
Smith: Not available  
dsDNA: Not available  
Antinuclear antibody: 
2560 
Ro: Positive (240) 
La: Positive(320) 
1 month 3 months 
Not 
available  
Methylpredni-
solone 
[18] 
74 year-
old 
female   
SCLE 
Colon 
Cancer 
capecitabine 
Red annular 
scaling lesions 
Face, arms, 
hands, feet 
Histone: Negative 
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody: 
1000 
Ro: Positive 
La: Positive 
2 weeks 2 weeks 
Not 
available  
Hydroxychloro-
quine 
Topical steroid 
Retinoid 
[19] 
77 year-
old 
female   
SCLE 
Gastric 
cancer 
5-fluorouracil  
 
Red scaling 
plaques 
Face, chest,  
forearms, 
hands 
Histone: Negative 
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody: Not 
available  
Ro: Positive (82.7) 
La: Negative 
7 days 6 weeks 
Not 
available  
Topical steroid 
Photoprotection 
[20] 
78 year-
old 
female  
SCLE  BRCA capecitabine 
Annular red 
scaling 
plaques 
Face, neck, 
upper back, 
forearms 
Histone: Negative 
Smith: Not available  
dsDNA: Negative 
Antinuclear antibody: 640 
Ro: Positive (4.93) 
La: Negative 
10 days 3 weeks 
Not 
available  
None [21] 
78 year-
old 
female  
DLE 
Gastric  
Cancer  
uracil-tegafur  
Annular 
Scaly pink/ 
violaceous/ 
red scaly 
plaques 
Face  
Histone: Not available  
Smith: Not available  
dsDNA: Positive (19) 
Antinuclear antibody: 
2560 
Ro: Positive(256) 
La: Positive(7 ) 
30 
months 
6 months 
Still 
elevated 
at 6 
months 
Not available  [7] 
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78 year-
old male  
SLE 
Pancreatic 
cancer 
uracil-tegafur  
Erythema and 
blisters 
Face 
Histone: Not available  
Smith: Positive (23.3) 
dsDNA: Negative 
Antinuclear antibody: 640 
Ro: Positive (129) 
La: Positive (207) 
4 months 2 weeks 6 months Topical steroid [22] 
 
Dem – Demographics; dsDNA – double-stranded DNA; Ro – Anti-Sjögren's-syndrome-related antigen A; La – Anti-Sjögren's-syndrome-related antigen B; DLE – Discoid lupus 
erythematosus; anti-histone antibodies Histone); Smith – anti-Smith antibodies; Ref – References; SCLE – Subacute cutaneous lupus erythematosus; SLE – Systemic lupus 
erythematosus; TRA – Time to resolution of antibodies; TRR – Time to resolution of rash; TX – Treatment 
 
 
 
 
Table 2. Types of drug-induced lupus erythematosus induced by 5-fluorouracil and its analogues. 
 
 SLE DLE SCLE 
5-fluorouracil    
Capecitabine    
Uracil-tegafur    
 
